Browse NR4A3

Summary
SymbolNR4A3
Namenuclear receptor subfamily 4, group A, member 3
Aliases CSMF; MINOR; chondrosarcoma, extraskeletal myxoid, fused to EWS; mitogen-induced nuclear orphan receptor; ne ......
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF00104 Ligand-binding domain of nuclear hormone receptor
PF00105 Zinc finger
Function

Transcriptional activator that binds to regulatory elements in promoter regions in a cell- and response element (target)-specific manner. Induces gene expression by binding as monomers to the NR4A1 response element (NBRE) 5'-AAAAGGTCA-3' site and as homodimers to the Nur response element (NurRE) site in the promoter of their regulated target genes (By similarity). Plays a role in the regulation of proliferation, survival and differentiation of many different cell types and also in metabolism and inflammation. Mediates proliferation of vascular smooth muscle, myeloid progenitor cell and type B pancreatic cells; promotes mitogen-induced vascular smooth muscle cell proliferation through transactivation of SKP2 promoter by binding a NBRE site (By similarity). Upon PDGF stimulation, stimulates vascular smooth muscle cell proliferation by regulating CCND1 and CCND2 expression. In islets, induces type B pancreatic cell proliferation through up-regulation of genes that activate cell cycle, as well as genes that cause degradation of the CDKN1A (By similarity). Negatively regulates myeloid progenitor cell proliferation by repressing RUNX1 in a NBRE site-independent manner. During inner ear, plays a role as a key mediator of the proliferative growth phase of semicircular canal development (By similarity). Mediates also survival of neuron and smooth muscle cells; mediates CREB-induced neuronal survival, and during hippocampus development, plays a critical role in pyramidal cell survival and axonal guidance. Is required for S phase entry of the cell cycle and survival of smooth muscle cells by inducing CCND1, resulting in RB1 phosphorylation. Binds to NBRE motif in CCND1 promoter, resulting in the activation of the promoter and CCND1 transcription (By similarity). Plays also a role in inflammation; upon TNF stimulation, mediates monocyte adhesion by inducing the expression of VCAM1 and ICAM1 by binding to the NBRE consensus site (By similarity) (PubMed:20558821). In mast cells activated by Fc-epsilon receptor cross-linking, promotes the synthesis and release of cytokines but impairs events leading to degranulation (By similarity). Plays also a role in metabolism; by modulating feeding behavior; and by playing a role in energy balance by inhibiting the glucocorticoid-induced orexigenic neuropeptides AGRP expression, at least in part by forming a complex with activated NR3C1 on the AGRP- glucocorticoid response element (GRE), and thus weakening the DNA binding activity of NR3C1. Upon catecholamines stimulation, regulates gene expression that controls oxidative metabolism in skeletal muscle (By similarity). Plays a role in glucose transport by regulating translocation of the SLC2A4 glucose transporter to the cell surface (PubMed:24022864). Finally, during gastrulation plays a crucial role in the formation of anterior mesoderm by controlling cell migration. Inhibits adipogenesis (By similarity). Also participates in cardiac hypertrophy by activating PARP1 (By similarity).

> Gene Ontology
 
Biological Process GO:0000302 response to reactive oxygen species
GO:0001704 formation of primary germ layer
GO:0001707 mesoderm formation
GO:0001819 positive regulation of cytokine production
GO:0002263 cell activation involved in immune response
GO:0002274 myeloid leukocyte activation
GO:0002275 myeloid cell activation involved in immune response
GO:0002279 mast cell activation involved in immune response
GO:0002366 leukocyte activation involved in immune response
GO:0002367 cytokine production involved in immune response
GO:0002429 immune response-activating cell surface receptor signaling pathway
GO:0002431 Fc receptor mediated stimulatory signaling pathway
GO:0002440 production of molecular mediator of immune response
GO:0002443 leukocyte mediated immunity
GO:0002444 myeloid leukocyte mediated immunity
GO:0002448 mast cell mediated immunity
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002699 positive regulation of immune effector process
GO:0002700 regulation of production of molecular mediator of immune response
GO:0002702 positive regulation of production of molecular mediator of immune response
GO:0002718 regulation of cytokine production involved in immune response
GO:0002720 positive regulation of cytokine production involved in immune response
GO:0002757 immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0003012 muscle system process
GO:0003300 cardiac muscle hypertrophy
GO:0006090 pyruvate metabolic process
GO:0006091 generation of precursor metabolites and energy
GO:0006352 DNA-templated transcription, initiation
GO:0006367 transcription initiation from RNA polymerase II promoter
GO:0006631 fatty acid metabolic process
GO:0006887 exocytosis
GO:0006979 response to oxidative stress
GO:0007159 leukocyte cell-cell adhesion
GO:0007369 gastrulation
GO:0007409 axonogenesis
GO:0007411 axon guidance
GO:0007423 sensory organ development
GO:0007498 mesoderm development
GO:0007631 feeding behavior
GO:0008643 carbohydrate transport
GO:0008645 hexose transport
GO:0009444 pyruvate oxidation
GO:0009755 hormone-mediated signaling pathway
GO:0010035 response to inorganic substance
GO:0010565 regulation of cellular ketone metabolic process
GO:0010611 regulation of cardiac muscle hypertrophy
GO:0010613 positive regulation of cardiac muscle hypertrophy
GO:0010827 regulation of glucose transport
GO:0010828 positive regulation of glucose transport
GO:0014742 positive regulation of muscle hypertrophy
GO:0014743 regulation of muscle hypertrophy
GO:0014896 muscle hypertrophy
GO:0014897 striated muscle hypertrophy
GO:0015749 monosaccharide transport
GO:0015758 glucose transport
GO:0015980 energy derivation by oxidation of organic compounds
GO:0019216 regulation of lipid metabolic process
GO:0019217 regulation of fatty acid metabolic process
GO:0019395 fatty acid oxidation
GO:0021537 telencephalon development
GO:0021543 pallium development
GO:0021761 limbic system development
GO:0021766 hippocampus development
GO:0022407 regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0030258 lipid modification
GO:0030522 intracellular receptor signaling pathway
GO:0030534 adult behavior
GO:0030900 forebrain development
GO:0031099 regeneration
GO:0031100 animal organ regeneration
GO:0032418 lysosome localization
GO:0032762 mast cell cytokine production
GO:0032763 regulation of mast cell cytokine production
GO:0032765 positive regulation of mast cell cytokine production
GO:0032844 regulation of homeostatic process
GO:0033002 muscle cell proliferation
GO:0033003 regulation of mast cell activation
GO:0033005 positive regulation of mast cell activation
GO:0034440 lipid oxidation
GO:0034599 cellular response to oxidative stress
GO:0034614 cellular response to reactive oxygen species
GO:0035239 tube morphogenesis
GO:0035726 common myeloid progenitor cell proliferation
GO:0036473 cell death in response to oxidative stress
GO:0036474 cell death in response to hydrogen peroxide
GO:0036475 neuron death in response to oxidative stress
GO:0036476 neuron death in response to hydrogen peroxide
GO:0038093 Fc receptor signaling pathway
GO:0038095 Fc-epsilon receptor signaling pathway
GO:0038097 positive regulation of mast cell activation by Fc-epsilon receptor signaling pathway
GO:0042180 cellular ketone metabolic process
GO:0042471 ear morphogenesis
GO:0042472 inner ear morphogenesis
GO:0042542 response to hydrogen peroxide
GO:0043299 leukocyte degranulation
GO:0043303 mast cell degranulation
GO:0043401 steroid hormone mediated signaling pathway
GO:0043434 response to peptide hormone
GO:0043435 response to corticotropin-releasing hormone
GO:0043500 muscle adaptation
GO:0043502 regulation of muscle adaptation
GO:0043523 regulation of neuron apoptotic process
GO:0043524 negative regulation of neuron apoptotic process
GO:0043583 ear development
GO:0044057 regulation of system process
GO:0044320 cellular response to leptin stimulus
GO:0044321 response to leptin
GO:0044342 type B pancreatic cell proliferation
GO:0044708 single-organism behavior
GO:0045055 regulated exocytosis
GO:0045333 cellular respiration
GO:0045444 fat cell differentiation
GO:0045576 mast cell activation
GO:0045785 positive regulation of cell adhesion
GO:0045787 positive regulation of cell cycle
GO:0045834 positive regulation of lipid metabolic process
GO:0045923 positive regulation of fatty acid metabolic process
GO:0046320 regulation of fatty acid oxidation
GO:0046321 positive regulation of fatty acid oxidation
GO:0048332 mesoderm morphogenesis
GO:0048520 positive regulation of behavior
GO:0048545 response to steroid hormone
GO:0048562 embryonic organ morphogenesis
GO:0048568 embryonic organ development
GO:0048659 smooth muscle cell proliferation
GO:0048660 regulation of smooth muscle cell proliferation
GO:0048661 positive regulation of smooth muscle cell proliferation
GO:0048667 cell morphogenesis involved in neuron differentiation
GO:0048752 semicircular canal morphogenesis
GO:0048839 inner ear development
GO:0048871 multicellular organismal homeostasis
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0050679 positive regulation of epithelial cell proliferation
GO:0050795 regulation of behavior
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050885 neuromuscular process controlling balance
GO:0050905 neuromuscular process
GO:0051402 neuron apoptotic process
GO:0051640 organelle localization
GO:0051656 establishment of organelle localization
GO:0060004 reflex
GO:0060005 vestibular reflex
GO:0060259 regulation of feeding behavior
GO:0060872 semicircular canal development
GO:0061081 positive regulation of myeloid leukocyte cytokine production involved in immune response
GO:0061082 myeloid leukocyte cytokine production
GO:0061469 regulation of type B pancreatic cell proliferation
GO:0061564 axon development
GO:0070301 cellular response to hydrogen peroxide
GO:0070486 leukocyte aggregation
GO:0070487 monocyte aggregation
GO:0070997 neuron death
GO:0071375 cellular response to peptide hormone stimulus
GO:0071376 cellular response to corticotropin-releasing hormone stimulus
GO:0071383 cellular response to steroid hormone stimulus
GO:0071396 cellular response to lipid
GO:0071407 cellular response to organic cyclic compound
GO:0071417 cellular response to organonitrogen compound
GO:0071867 response to monoamine
GO:0071868 cellular response to monoamine stimulus
GO:0071869 response to catecholamine
GO:0071870 cellular response to catecholamine stimulus
GO:0071887 leukocyte apoptotic process
GO:0090257 regulation of muscle system process
GO:0090596 sensory organ morphogenesis
GO:0097009 energy homeostasis
GO:0097485 neuron projection guidance
GO:1900407 regulation of cellular response to oxidative stress
GO:1900408 negative regulation of cellular response to oxidative stress
GO:1900623 regulation of monocyte aggregation
GO:1900625 positive regulation of monocyte aggregation
GO:1901031 regulation of response to reactive oxygen species
GO:1901032 negative regulation of response to reactive oxygen species
GO:1901214 regulation of neuron death
GO:1901215 negative regulation of neuron death
GO:1901652 response to peptide
GO:1901653 cellular response to peptide
GO:1902882 regulation of response to oxidative stress
GO:1902883 negative regulation of response to oxidative stress
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
GO:1903201 regulation of oxidative stress-induced cell death
GO:1903202 negative regulation of oxidative stress-induced cell death
GO:1903203 regulation of oxidative stress-induced neuron death
GO:1903204 negative regulation of oxidative stress-induced neuron death
GO:1903205 regulation of hydrogen peroxide-induced cell death
GO:1903206 negative regulation of hydrogen peroxide-induced cell death
GO:1903207 regulation of hydrogen peroxide-induced neuron death
GO:1903208 negative regulation of hydrogen peroxide-induced neuron death
GO:2000106 regulation of leukocyte apoptotic process
GO:2000108 positive regulation of leukocyte apoptotic process
GO:2000253 positive regulation of feeding behavior
GO:2000505 regulation of energy homeostasis
Molecular Function GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding
GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0000987 core promoter proximal region sequence-specific DNA binding
GO:0001046 core promoter sequence-specific DNA binding
GO:0001047 core promoter binding
GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001159 core promoter proximal region DNA binding
GO:0001221 transcription cofactor binding
GO:0001223 transcription coactivator binding
GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0003707 steroid hormone receptor activity
GO:0004879 RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding
GO:0004887 thyroid hormone receptor activity
GO:0008134 transcription factor binding
GO:0035035 histone acetyltransferase binding
GO:0035257 nuclear hormone receptor binding
GO:0035258 steroid hormone receptor binding
GO:0035259 glucocorticoid receptor binding
GO:0051427 hormone receptor binding
GO:0098531 transcription factor activity, direct ligand regulated sequence-specific DNA binding
Cellular Component GO:0005667 transcription factor complex
GO:0042629 mast cell granule
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-383280: Nuclear Receptor transcription pathway
Summary
SymbolNR4A3
Namenuclear receptor subfamily 4, group A, member 3
Aliases CSMF; MINOR; chondrosarcoma, extraskeletal myxoid, fused to EWS; mitogen-induced nuclear orphan receptor; ne ......
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between NR4A3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolNR4A3
Namenuclear receptor subfamily 4, group A, member 3
Aliases CSMF; MINOR; chondrosarcoma, extraskeletal myxoid, fused to EWS; mitogen-induced nuclear orphan receptor; ne ......
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of NR4A3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.65 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolNR4A3
Namenuclear receptor subfamily 4, group A, member 3
Aliases CSMF; MINOR; chondrosarcoma, extraskeletal myxoid, fused to EWS; mitogen-induced nuclear orphan receptor; ne ......
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of NR4A3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1590.804
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3610.731
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0390.972
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.9240.116
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.8310.719
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.0410.726
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.5210.415
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.1930.34
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.180.892
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.4610.204
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.660.188
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2710.312
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of NR4A3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolNR4A3
Namenuclear receptor subfamily 4, group A, member 3
Aliases CSMF; MINOR; chondrosarcoma, extraskeletal myxoid, fused to EWS; mitogen-induced nuclear orphan receptor; ne ......
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NR4A3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolNR4A3
Namenuclear receptor subfamily 4, group A, member 3
Aliases CSMF; MINOR; chondrosarcoma, extraskeletal myxoid, fused to EWS; mitogen-induced nuclear orphan receptor; ne ......
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NR4A3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NR4A3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolNR4A3
Namenuclear receptor subfamily 4, group A, member 3
Aliases CSMF; MINOR; chondrosarcoma, extraskeletal myxoid, fused to EWS; mitogen-induced nuclear orphan receptor; ne ......
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NR4A3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolNR4A3
Namenuclear receptor subfamily 4, group A, member 3
Aliases CSMF; MINOR; chondrosarcoma, extraskeletal myxoid, fused to EWS; mitogen-induced nuclear orphan receptor; ne ......
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of NR4A3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolNR4A3
Namenuclear receptor subfamily 4, group A, member 3
Aliases CSMF; MINOR; chondrosarcoma, extraskeletal myxoid, fused to EWS; mitogen-induced nuclear orphan receptor; ne ......
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between NR4A3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolNR4A3
Namenuclear receptor subfamily 4, group A, member 3
Aliases CSMF; MINOR; chondrosarcoma, extraskeletal myxoid, fused to EWS; mitogen-induced nuclear orphan receptor; ne ......
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting NR4A3 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting NR4A3.
ID Name Drug Type Targets #Targets
DB01254DasatinibSmall MoleculeABL1, ABL2, BCR, BTK, CSK, EPHA2, EPHA5, EPHB4, FGR, FRK, FYN, HSP ......22